Connect with us

News

ESMO 2020: Cabometyx® (cabozantinib) in Combination With Opdivo® (nivolumab) Demonstrates Significant Survival Benefits in Patients With Advanced Renal Cell Carcinoma in Pivotal Phase III CheckMate -9ER Trial

gbafNews28

Regulatory News:

Ipsen (Euronext: IPN; ADR: IPSEY) today announced the first presentation of results from the pivotal Phase III CheckMate -9ER trial, in which Cabometyx (cabozantinib) in combination with Bristol Myers Squibbs Opdivo (nivolumab) demonstrated significant improvements across all efficacy endpoints, including overall survival (OS), in previously untreated advanced renal cell carcinoma (RCC).1

Cabometyx in combination with Opdivo reduced the risk of death by 40% versus sunitinib (HR: 0.60 [98.89% Confidence Interval [CI]: 0.40“0.89]; p= 0.0010; median OS not reached in either arm). In patients receiving Cabometyx in combination with Opdivo, median progression-free survival (PFS), the trials primary endpoint, was doubled compared to those receiving sunitinib alone: 16.6 months versus 8.3 months respectively (Hazard Ratio [HR]: 0.51 [95% CI 0.41“0.64], p < 0.0001).

In addition, Cabometyx in combination with Opdivo demonstrated a superior objective response rate, with twice as many patients responding compared to sunitinib (56% vs. 27%; p<0.0001), and 8% versus 5% achieved a complete response. Cabometyx in combination with Opdivo was associated with a longer duration of response than sunitinib, with a median duration of 20.2 months versus 11.5 months. Additionally, patients treated with the combination had a much lower rate of treatment discontinuation versus sunitinib (44.4% vs. 71.3%), and a significantly lower rate of treatment discontinuation due to disease progression versus sunitinib (27.8% vs. 48.1%). All these key efficacy results were consistent across the pre-specified International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) risk and PD-L1 subgroups.

While weve seen considerable progress in the treatment of metastatic renal cell carcinoma, we must continue to research new options to help more patients achieve positive outcomes, said Dr. Toni Choueiri, Director of the Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute and Jerome and Nancy Kohlberg Professor of Medicine at Harvard Medical School. The CheckMate -9ER data demonstrate meaningful efficacy benefits with nivolumab plus cabozantinib, which significantly improved overall survival and doubled progression-free survival and objective response rate with consistent effects observed across pre-specified subgroups. These results, along with a favorable tolerability profile and superior health-related quality of life, highlight this regimens potential importance among combinations of immunotherapies and tyrosine kinase inhibitors.

Cabometyx in combination with Opdivo was well tolerated and reflected the known safety profiles of the immunotherapy and tyrosine kinase inhibitor components in previously untreated advanced RCC. The incidence of treatment-related adverse events (TRAEs), including any-grade and high- grade TRAEs, was slightly higher for Cabometyx in combination with Opdivo versus sunitinib (97% versus 93% for any-grade; 61% versus 51% for grade 3 and higher), with a low rate of treatment- related discontinuations (7% for Cabometyx only, 6% for Opdivo only, and 3% for both Cabometyx and Opdivo versus 9% for sunitinib). Patients treated with Cabometyx in combination with Opdivo reported significantly better health-related quality of life than those treated with sunitinib at most time points, according to National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy (FACT)-Kidney Symptom Index 19 (FKSI-19) scores.

Europe has some of the highest rates of kidney cancer in the world. By meeting all three efficacy endpoints, CheckMate -9ER means physicians treating first-line aRCC can consider this combination to potentially improve treatment outcomes for patients with rapidly progressive disease, and for patients, this may translate into improved health-related quality of life, said Dr. Cristina Su¡rez, Medical Oncologist at the Vall d´Hebron University Hospital, in Barcelona, Spain and a lead investigator on the Phase III CheckMate -9ER trial.

Dr. Howard Mayer, Executive Vice President and Head of Research and Development at Ipsen added: These positive results support the growing body of data on the utility of Cabometyx and its ability to create a more immune-permissive tumor environment that could enhance the response to immune checkpoint inhibitors. We look forward to discussing these results with global health authorities with the aim to bring this new combination regimen to previously untreated kidney cancer patients, a population that, despite recent advances, remains in need of additional therapeutic options that extend survival and improve quality of life.

These results (Presentation #696O_PR) will be featured as a Proffered Paper during a Presidential Symposium at the European Society for Medical Oncology (ESMO) Virtual Congress 2020, at 19:34 “ 19:46 CEST on 19 September.

Based on these efficacy and safety results from CheckMate -9ER, Ipsen and Bristol Myers Squibb have each submitted type II variation applications for Cabometyx in combination with Opdivo to the European Medicines Agency (EMA). On 12 September, the EMA validated the type II variations, confirming the submissions are complete and beginning the EMAs centralized review process. In addition, Bristol Myers Squibb and Exelixis, which has exclusive rights to commercialize and develop Cabometyx in the U.S., recently completed their respective U.S. FDA submissions for Cabometyx in combination with Opdivo and for Opdivo in combination with Cabometyx, and along with their partners, they plan to discuss the CheckMate -9ER data with regulatory authorities across the world.

About renal cell carcinoma There are over 400,000 new cases of kidney cancer diagnosed worldwide each year.3 Of these, renal cell carcinoma (RCC) is the most common type of kidney cancer, accounting for approximately 90% of cases.4,5 It is twice as common in men, and male patients account for over two thirds of deaths.3 If detected in the early stages, the five-year survival rate is high, but for patients with advanced or late-stage metastatic RCC the survival rate is much lower, around 12%, with no identified cure for this disease.6,7

About the CheckMate -9ER trial CheckMate -9ER is an open-label, randomized, multi-national Phase III trial evaluating patients with previously untreated advanced or metastatic RCC. A total of 651 patients (23% favorable risk, 58% intermediate risk, 20% poor risk; 25% PD-L1 ‰¥1%) were randomized to Cabometyx plus Opdivo (n = 323) versus sunitinib (n = 328). The primary endpoint is progression-free survival (PFS). Secondary endpoints include overall survival (OS) and objective response rate (ORR). The primary efficacy analysis is comparing the doublet combination versus sunitinib in all randomized patients. The trial is sponsored by Bristol Myers Squibb and Ono Pharmaceutical Co and co-funded by Exelixis, Ipsen and Takeda Pharmaceutical Company Limited.

About Cabometyx (cabozantinib) Cabometyx is currently approved in 54 countries, including in the European Union, the U.S., the U.K., Norway, Iceland, Australia, Switzerland, South Korea, Canada, Brazil, Taiwan, Hong Kong, Singapore, Macau, Jordan, Lebanon, Russian Federation, Ukraine, Turkey, United Arab Emirates, Saudi Arabia, Serbia, Israel, Mexico, Chile, Panama and New Zealand for the treatment of advanced RCC in adults who have received prior VEGF-targeted therapy; in the European Union, the U.K., Norway, Iceland, Canada, Australia, Brazil, Taiwan, Hong Kong, Singapore, Jordan, Russian Federation, Turkey, United Arab Emirates, Saudi Arabia, Israel, Mexico, Chile, Panama and New Zealand for previously untreated intermediate- or poor-risk advanced RCC; and in the European Union, the U.S., the U.K., Norway, Iceland, Canada, Australia, Switzerland, Saudi Arabia, Serbia, Israel, Taiwan, Hong Kong, South Korea, Singapore, Jordan, Russian Federation, Turkey, United Arab Emirates, Ukraine, Lebanon and Panama for HCC in adults who have previously been treated with sorafenib.

The detailed recommendations for the use of Cabometyx are described in the Summary of Product Characteristics (SmPC) and in the U.S. Prescribing Information (PI).

Cabometyx is marketed by Exelixis, Inc. in the United States and by Takeda Pharmaceutical Company Limited in Japan. Ipsen has exclusive rights for the commercialization and further clinical development of Cabometyx outside of the U.S. and Japan. Cabometyx is a registered trademark of Exelixis, Inc.

About Ipsen Ipsen is a global specialty-driven biopharmaceutical group focused on innovation and Specialty Care. The Group develops and commercializes innovative medicines in three key therapeutic areas “ Oncology, Neuroscience and Rare Diseases. Its commitment to oncology is exemplified through its growing portfolio of key therapies for prostate cancer, neuroendocrine tumors, renal cell carcinoma and pancreatic cancer. Ipsen also has a well-established Consumer Healthcare business. With total sales over ‚¬2.5 billion in 2019, Ipsen sells more than 20 drugs in over 115 countries, with a direct commercial presence in more than 30 countries. Ipsens R&D is focused on its innovative and differentiated technological platforms located in the heart of the leading biotechnological and life sciences hubs (Paris-Saclay, France; Oxford, UK; Cambridge, US). The Group has about 5,800 employees worldwide. Ipsen is listed in Paris (Euronext: IPN) and in the United States through a Sponsored Level I American Depositary Receipt program (ADR: IPSEY). For more information on Ipsen, visit www.ipsen.com.

Opdivo is a registered trademark of Bristol-Myers Squibb Company.

IpsenCautionary Note Regarding Forward-Looking Statements The forward-looking statements, objectives and targets contained herein are based on the Groups management strategy, current views and assumptions. Such statements involve known and unknown risks and uncertainties that may cause actual results, performance or events to differ materially from those anticipated herein. All of the above risks could affect the Groups future ability to achieve its financial targets, which were set assuming reasonable macroeconomic conditions based on the information available today. Use of the words “believes”, “anticipates” and “expects” and similar expressions are intended to identify forward-looking statements, including the Groups expectations regarding future events, including regulatory filings and determinations. Moreover, the targets described in this document were prepared without taking into account external growth assumptions and potential future acquisitions, which may alter these parameters. These objectives are based on data and assumptions regarded as reasonable by the Group. These targets depend on conditions or facts likely to happen in the future, and not exclusively on historical data. Actual results may depart significantly from these targets given the occurrence of certain risks and uncertainties, notably the fact that a promising product in early development phase or clinical trial may end up never being launched on the market or reaching its commercial targets, notably for regulatory or competition reasons and also taking into consideration assessment delays of certain clinical trials in light of the ongoing COVID-19 pandemic. The Group must face or might face competition from generic products that might translate into a loss of market share. Furthermore, the Research and Development process involves several stages each of which involves the substantial risk that the Group may fail to achieve its objectives and be forced to abandon its efforts with regards to a product in which it has invested significant sums. Therefore, the Group cannot be certain that favorable results obtained during pre-clinical trials will be confirmed subsequently during clinical trials, or that the results of clinical trials will be sufficient to demonstrate the safe and effective nature of the product concerned. There can be no guarantees a product will receive the necessary regulatory approvals or that the product will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward- looking statements. Other risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the Group’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the Groups patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions. The Group also depends on third parties to develop and market some of its products which could potentially generate substantial royalties; these partners could behave in such ways which could cause damage to the Groups activities and financial results. The Group cannot be certain that its partners will fulfil their obligations. It might be unable to obtain any benefit from those agreements. A default by any of the Groups partners could generate lower revenues than expected. Such situations could have a negative impact on the Groups business, financial position or performance. The Group expressly disclaims any obligation or undertaking to update or revise any forward-looking statements, targets or estimates contained in this press release to reflect any change in events, conditions, assumptions or circumstances on which any such statements are based, unless so required by applicable law. The Groups business is subject to the risk factors outlined in its registration documents filed with the French Autorit des Marchs Financiers. The risks and uncertainties set out are not exhaustive and the reader is advised to refer to the Groups 2018 Registration Document available on its website (www.ipsen.com).

References

  1. ESMO Virtual Congress 2020: Abstracts. ESMO. Accessed: September 2020. Available: https://cslide.ctimeetingtech.com/esmo2020/attendee/confcal_2/presentation
  2. World Cancer Research Fund. 2020. Kidney Cancer Statistics. Last accessed: September 2020. Available from: https://www.wcrf.org/dietandcancer/cancer-trends/kidney-cancer-statistics
  3. GLOBOCAN 2018. Kidney Cancer Factsheet. Last accessed: September 2020. Available from: https://gco.iarc.fr/today/data/factsheets/cancers/29-Kidney-fact-sheet.pdf
  4. Mayo Clinic. Kidney Cancer. Last accessed: September 2020. Available from: https://www.mayoclinic.org/diseases-conditions/kidney-cancer/symptoms-causes/syc-20352664
  5. National Cancer Institute. Renal Cell Cancer. Last accessed: September 2020. Available from: https://www.cancer.gov/types/kidney/patient/kidney-treatment-pdq
  6. American Cancer Society. Survival rates for kidney cancer. Last accessed: September 2020. Available from: https://www.cancer.org/cancer/kidney-cancer/detection-diagnosis-staging/survival-rates.html
  7. Renal cell carcinomas epidemiology in the era of widespread imaging. Journal of Clinical Oncology. 2019; 37:15. DOI: 10.1200/JCO.2019.37.15_suppl.e1308

Disclaimer: Intended for international media and investor audiences only

Media

Fanny Allaire

Global Communications Director

+33 (0) 6 08 91 92 55

[email protected]

Financial Community

Myriam Koutchinsky Investor Relations Manager

+33 (0)1 58 33 51 04

[email protected]

News

YOFC Presents at China International Information and Communications Exhibition 2020

gbafNews28

BEIJING, Oct. 20, 2020 /PRNewswire/ — Along with its product lineup and solutions designed to empower the deployment of 5G Internet, leading edge and intelligent applications in the future, Yangtze Optical Fibre and Cable Joint Stock Limited Company ("YOFC" or "the Company") (601869.SH, 06869.HK), a global leading optical fibre and cable provider, attended the China International Information and Communications Exhibition (PT Expo) 2020 organized by the Ministry of Industry and Information Technology of China.

YOFC's Exhibition Booth at China International Information and Communications Exhibition 2020
YOFC’s Exhibition Booth at China International Information and Communications Exhibition 2020

At the YOFC booth, the Company’s Space Division Multiplexing (SDM) solution for next-generation data centres took central stage. The solution was created based on new multi-core fibre technology, suitable for 800Gb and beyond systems, addressing the urgent demands of data centres for bigger capacity, longer transmission distance, high-density connections and low energy consumption. Also sharing the spotlight was the Company’s latest innovations in optical communications and materials.

New Products and Solutions Helping to Develop New Infrastructure Powered by Next-Gen Information Networks and 5G

YOFC’s robust industrial expertise and over 30-year exploration in ICT have enabled the Company to flesh out a product and solution roadmap that empowers the development of a new type of infrastructure enabled by next-gen information networks. With a global rollout of 5G on the horizon, YOFC showcased innovations covering five main categories to meet with pressing new infrastructure needs in the 5G era, which are 5G Series Products and Solutions, Power Grid Communication, Industrial Internet, Big Data Centers and Rail Transportation.

Building a robust 5G ecosystem requires new fibre, cable and optical modules with excellent quality and high efficiency. YOFC has developed solutions for various intelligent applications that will help accelerate a transition to 5G and the Internet of Everything. As part of the product lineup and solutions for 5G facilities, YOFC showcased MWDM Front-haul Solution,Cable Solution for Carrier Network and Optical Transceiver for 5G.

For the sophisticated and complex networks of ultra-high-voltage electricity transmission (UHV), To address these challenges, YOFC presented its latest products designed for a cleaner, safer, and more efficient modern energy system. Amongst these offerings, the G.654.E fibre features ultra-low attenuation with a large effective area, high-fibre-count OPGW cables, and icing monitoring system.

Green, flexible, fast and intelligent, these are some of the key features that define the future of big data centres. YOFC has developed integrated cabling solutions for data centres that feature high density, high performance, reliability and scalability. Products such as optical transceivers and all-in-one cabinets using edge-computing-integrated infrastructure, achieve more effective connectivity and reliable security for network transmission and information processing for data centres.

For rail transportation, YOFC has been leveraging its strength in cable manufacturing to develop numerous technologies for urban rail transit that achieve full bands, wide coverage and low attenuation, including 5G broadband radiation-mode leaky coaxial cable, distributed temperature system and distributed vibration monitoring system. These technologies accommodate the demands of urban rail systems for communication and promote the application of digital technologies in urban rail transportation.

Smart Ocean and Home Solutions

YOFC offers diversified products and solutions for smart tourism, smart communities, and smart education that provide a wide range of smart services, focuses on F5G all-optical network and transforming from "Fibre to the Home (FTTH)" to "Fibre to Everywhere" by expanding the application of the optical technology to all service scenarios. At the exhibition, YOFC presented its key technologies for the ocean and home.

  • Smart Ocean Solutions: YOFC showcased submarine optical cables to be used in various transoceanic communication systems applicable for both deep and shallow sea. The solution also features alternating (direct) current submarine (photoelectric composite) cables for power transmission;
  • Smart Home Solutions: including YOFC’s original BendRobust™ speciality bend-resistant fibre and self-developed high-efficiency photoelectric conversion chip which can maintain high performance and stability across various complex environments.

As information and communication technology (ICT) continues to revolutionize people’s way of life, YOFC continues its commitment to the core mission of establishing a smart link to create a better life, and serving global customers with innovation-led, high-performance and high-quality products; joining efforts with global partners to build a brighter future.

Related Stocks:
HongKong: 06869  
Shanghai: 601869 

Related Links:
https://en.yofc.com/

Related Links :

http://www.yofc.com

Continue Reading

News

IT Tech Packaging, Inc. Participated the ALL IN PRINT CHINA Exhibition

gbafNews28

BAODING, China, Oct. 20, 2020 /PRNewswire/ — IT Tech Packaging, Inc. (NYSE MKT: ITP) ("IT Tech Packaging" or "the Company"), a leading manufacturer and distributor of diversified paper products in North China, today announced its CEO Mr. Zhenyong Liu together with its marketing team participated The 8th All In Print China Exhibition held in Shanghai City, the first comprehensive exhibition in printing and packaging business after the COVID-19 epidemic outbreak. The roaring trade released a strong signal of the positive recovery of the printing and packaging industry.

ITP partivipated The All In Print China
ITP partivipated The All In Print China

Mr. Zhenyong Liu, the CEO and Chairman of the Company commented: "the printing and packaging industry is improving as the domestic economy continues recovering, and so is the company. The two-day visit gave us a deep understanding about the latest materials, techniques and products. We will follow the industry trend and strive for a better performance with more advanced producing technology and product quality."

About IT Tech Packaging, Inc.

Founded in 1996, IT Tech Packaging, Inc. is a leading manufacturer and distributor of diversified paper products in North China. Using recycled paper as its primary raw material (with the exception of its tissue paper products), ITP produces and distributes three categories of paper products: corrugating medium paper, offset printing paper and tissue paper products. With production based in Baoding and Xingtai in North China’s Hebei Province, ITP is located strategically close to the Beijing and Tianjin region, home to a growing base of industrial and manufacturing activities and one of the largest markets for paper products consumption in the country. ITP has been listed on the NYSE MKT since December 2009.

Safe Harbor Statements

This press release may contain forward-looking statements. These forward-looking statements involve inherent risks and uncertainties that could cause actual results to differ materially from those projected or anticipated, including risks outlined in the Company’s public filings with the Securities and Exchange Commission, including the Company’s latest annual report on Form 10-K. All information provided in this press release speaks as of the date hereof. Except as otherwise required by law, the Company undertakes no obligation to update or revise its forward-looking statements.

For more information, please contact:

At the Company Email:
[email protected]
Tel: +86 0312 8698215

Related Links :

http://www.itpackaging.cn/

Continue Reading

News

Senmiao Technology Announces Signing of Framework Agreement with BYD to Purchase and Jointly Promote Electric Vehicles for Ride-Sharing

gbafNews28

CHENGDU, China, Oct. 20, 2020 /PRNewswire/ — Senmiao Technology Limited ("Senmiao") (NASDAQ: AIHS), a provider of automobile transaction and related services targeting the online ride-hailing industry in China, today announced the signing of a Framework Agreement with BYD Auto Sales Co., Ltd., a wholly owned subsidiary of BYD Company Limited ("BYD",(HK:1211)), for the sale of BYD manufactured electric vehicles ("EVs") to Senmiao and joint promotion of EV vehicles for utilization in China’s ride-sharing or ride-hailing market.

Under the agreement, Senmiao has agreed to promote and give priority to BYD’s EVs for its leasing customers utilizing the vehicles for the purposes of ride-sharing, while BYD will provide favorable pricing, financial support, charging station priority, marketing, and after-sales service. As part of the agreement, Senmiao will provide an initial deposit and expects to purchase at least 5,000 vehicles from 2020 to 2021 to support expected ride-sharing growth.

Senmiao currently ranks first in the ride sharing market in large Chinese cities Chengdu (based in Sichuan Province with a population over 16 million) and Changsha (based in Hunan province with a population over 8 million).  Senmiao has focused on growing its leading position in its core markets, and believes this agreement will help to accelerate its growth given the high demand for EVs and energy efficient automobiles.

In April 2020, China announced a Three-Year-Blue-Sky-Action Plan to accelerate the adoption of EVs. In addition, following the impact of the COVID-19 pandemic, China extended monetary incentives and prolonged purchase-tax exemptions of new EVs through 2022.

BYD is one of the largest manufacturers of automobiles, battery-powered bicycles, buses, trucks, forklifts, solar panels, rechargeable batteries, and most notably mobile-phone batteries.

Xi Wen, Senmiao’s Chairman and Chief Executive Officer stated, "We are delighted to enter into this framework agreement with such a well-regarded company as BYD as we continue to promote the use of EVs in public transportation. We feel that the combination of our position in the ride-sharing markets where we operate along with the demand for EVs in China generally will be an exceptional fit for our customers. Our goal is to provide a wide range of financing and leasing options as we build out Senmiao’s network throughout China, and agreements such as this are instrumental to achieving appropriate scale."

Weiming Zhang, the vice general manager of BYD Auto Sales Co., Ltd. noted, "We are pleased to partner with Senmiao and look forward to supporting the expansion of EV automobiles in the ride-sharing market."

The framework agreement sets out the general terms of the parties intentions for their collaboration, with the goal reaching a more definitive agreement as the collaboration matures.

About Senmiao Technology Limited

Headquartered in Chengdu, Sichuan Province, Senmiao provides automobile transaction and related services including sales of automobiles, facilitation and services for automobile purchase and financing, management, operating lease, guarantee and other automobile transaction services aimed principally at the growing ride-sharing market in Senmiao’s areas of operation in China. For more information about Senmiao, please visit: http://www.senmiaotech.com.

Cautionary Note Regarding Forward-Looking Statements 

This press release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. These forward-looking statements also are subject to risks, uncertainties and assumptions, including those detailed from time to time in the Senmiao’s filings with the SEC, and represent Senmiao’s views only as of the date they are made and should not be relied upon as representing Senmiao’s views as of any subsequent date. Senmiao undertakes no obligation to publicly revise any forward-looking statements to reflect changes in events or circumstances. 

For more information, please contact:

At the Company:
Yiye Zhou
Email: [email protected]
Phone: +86 28 6155 4399

Investor Relations:

The Equity Group Inc. 
Adam Prior, Senior Vice President 
(212) 836-9606  
[email protected] 

In China
Lucy Ma, Associate
+86 10 5661 7012
[email protected]

© 2020 Senmiao Technology Ltd.  All rights reserved.

 

Related Links :

http://www.senmiaotech.com

Continue Reading
Editorial & Advertiser disclosureOur website provides you with information, news, press releases, Opinion and advertorials on various financial products and services. This is not to be considered as financial advice and should be considered only for information purposes. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third party websites, affiliate sales networks, and may link to our advertising partners websites. Though we are tied up with various advertising and affiliate networks, this does not affect our analysis or opinion. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you, or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish sponsored articles or links, you may consider all articles or links hosted on our site as a partner endorsed link.
gbafNews28 gbafNews28
News11 mins ago

Mercury Derivatives Trading Selects Eventus Systems for Trade Surveillance

Global Futures Proprietary Trading Firm Deploys Validus Platform AUSTIN, Texas, Oct. 20, 2020 /PRNewswire/ — Eventus Systems, Inc., a multi-award winning...

gbafNews28 gbafNews28
News11 mins ago

VolitionRx Limited Announces Details for Virtual Capital Markets Day 2020

AUSTIN, Texas, Oct. 20, 2020 /PRNewswire/ — VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") a multi-national epigenetics company developing simple, easy...

gbafNews28 gbafNews28
News11 mins ago

Samsung Biologics inks development partnership with Dinona for potential COVID-19 treatment

INCHEON, South Korea, Oct. 20, 2020 /PRNewswire/ — Samsung Biologics (207940.KS) has entered into a partnership agreement with biotech Dinona,...

gbafNews28 gbafNews28
News11 mins ago

CoinLock Announces Collaboration with Idoneus, IDON Token Available on Platform Today

– IDON luxury asset token to begin trading on the platform today. – IDON users can now enjoy more utility—like free hedging...

gbafNews28 gbafNews28
News11 mins ago

ATIF Holdings Limited Signs Letter of Intent to Acquire Illuminated Air Purification Solution Provider to Expand into Healthcare Technology Field

SHENZHEN, China, Oct. 20, 2020 /PRNewswire/ — ATIF Holdings Limited (Nasdaq: ATIF, the "Company"), a company providing business consulting and multimedia...

gbafNews28 gbafNews28
News11 mins ago

Over A Million Products On Sale During Banggood’s 11.11 Global Shopping Festival

GUANGZHOU, China, Oct. 20, 2020 /PRNewswire/ — Banggood, a leading cross-border e-commerce retailer, is offering exclusive discounts for its global...

gbafNews28 gbafNews28
News11 mins ago

Senmiao Technology Announces Signing of Framework Agreement with BYD to Purchase and Jointly Promote Electric Vehicles for Ride-Sharing

CHENGDU, China, Oct. 20, 2020 /PRNewswire/ — Senmiao Technology Limited ("Senmiao") (NASDAQ: AIHS), a provider of automobile transaction and related...

gbafNews28 gbafNews28
News11 mins ago

IT Tech Packaging, Inc. Participated the ALL IN PRINT CHINA Exhibition

BAODING, China, Oct. 20, 2020 /PRNewswire/ — IT Tech Packaging, Inc. (NYSE MKT: ITP) ("IT Tech Packaging" or "the Company"),...

gbafNews28 gbafNews28
News11 mins ago

YOFC Presents at China International Information and Communications Exhibition 2020

BEIJING, Oct. 20, 2020 /PRNewswire/ — Along with its product lineup and solutions designed to empower the deployment of 5G...

gbafNews28 gbafNews28
News11 mins ago

Aberdeen’s green stone coating expands into USA

TAIPEI, TAIWAN – Media OutReach – 20 October 2020 – The faux stone coating for buildings, a green product developed and...